share_log

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17

B of A Securities 维持对Amicus Therapeutics的买入,将目标股价上调至
Benzinga ·  2023/03/28 10:24

B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $16 to $17.

美国银行证券分析师塔辛·艾哈迈德维持Amicus Treateutics(纳斯达克:折叠)的买入,并将目标价从16美元上调至17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发